<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80794">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02151747</url>
  </required_header>
  <id_info>
    <org_study_id>4-2013-0889</org_study_id>
    <nct_id>NCT02151747</nct_id>
  </id_info>
  <brief_title>Testing BRCA 1/2 Mutation Using Next Generation Sequencing</brief_title>
  <acronym>BRCANGS</acronym>
  <official_title>Pilot Study of Validation of Testing BRCA 1/2 Mutation Using Next Generation Sequencing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Severance Hospital</source>
  <oversight_info>
    <authority>Republic of Korea: Ministry of Health and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Testing BRCA 1/2 mutation is important for patients with breast cancer, and Sanger
      sequencing is a standard method to identify BRCA 1/2 mutation. Next generation sequencing
      (NGS) is a high-throughput parallel sequencing that can provide genetic information with
      high accuracy. NGS is a faster and cost-effective method to detect gene mutations compared
      to Sanger sequencing. In this study, we evaluated the clinical role of NGS testing for BRCA
      1/2 compared to Sanger sequencing.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Overall Accuracy</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>after enrollment, comparison between Sanger and NGS method will be performed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, Specificity</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sensitivity and specificity of NGS</description>
  </secondary_outcome>
  <other_outcome>
    <measure>False negative and false positive rates</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>False negative and false positive rates of NGS</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Sanger</arm_group_label>
    <description>BRCA 1/2 test results by Sanger sequencing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGS</arm_group_label>
    <description>BRCA 1/2 test results by NGS</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with breast cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18

          -  Breast or ovarian cancer history in 2nd degree family members

          -  Male breast cancer

          -  Bilateral breast cancer

          -  Patient with breast cancer under 40 year of age

          -  Simultaneous breast and ovarian cancer

          -  Patients with epithelial ovarian cancer

          -  Breast cancer with other simultaneous extramammary malignancy

        Exclusion Criteria:

        -Patients who do not agree with testing BRCA 1/2 mutation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung IL Kim, MD, phD</last_name>
    <role>Study Director</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JH Sohn, MD,phD</last_name>
    <role>Study Director</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>May 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Severance Hospital</investigator_affiliation>
    <investigator_full_name>Hyung Seok Park</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>breast neoplasms, BRCA1, Sanger, NGS, Next generation sequencing</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
